- Home
- FNLC vs DBVT Comparison
FNLC vs DBVT Comparison
Compare FNLC & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- DBVT
- Stock Information
- Founded
- FNLC 1864
- DBVT 2002
- Country
- FNLC United States
- DBVT France
- Employees
- FNLC N/A
- DBVT N/A
- Industry
- FNLC Major Banks
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FNLC Finance
- DBVT Health Care
- Exchange
- FNLC Nasdaq
- DBVT Nasdaq
- Market Cap
- FNLC 284.0M
- DBVT 250.5M
- IPO Year
- FNLC 1999
- DBVT N/A
- Fundamental
- Price
- FNLC $25.82
- DBVT $10.80
- Analyst Decision
- FNLC
- DBVT Buy
- Analyst Count
- FNLC 0
- DBVT 4
- Target Price
- FNLC N/A
- DBVT $14.81
- AVG Volume (30 Days)
- FNLC 26.6K
- DBVT 26.4K
- Earning Date
- FNLC 07-23-2025
- DBVT 07-29-2025
- Dividend Yield
- FNLC 5.54%
- DBVT N/A
- EPS Growth
- FNLC 1.61
- DBVT N/A
- EPS
- FNLC 2.52
- DBVT N/A
- Revenue
- FNLC $82,116,000.00
- DBVT $3,497,000.00
- Revenue This Year
- FNLC N/A
- DBVT $1,700.53
- Revenue Next Year
- FNLC N/A
- DBVT $535.67
- P/E Ratio
- FNLC $10.25
- DBVT N/A
- Revenue Growth
- FNLC 5.28
- DBVT N/A
- 52 Week Low
- FNLC $22.11
- DBVT $2.21
- 52 Week High
- FNLC $31.05
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- FNLC 57.54
- DBVT 58.42
- Support Level
- FNLC $25.44
- DBVT $10.53
- Resistance Level
- FNLC $27.58
- DBVT $11.33
- Average True Range (ATR)
- FNLC 0.66
- DBVT 0.76
- MACD
- FNLC 0.12
- DBVT 0.14
- Stochastic Oscillator
- FNLC 60.05
- DBVT 65.90
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.